Literature DB >> 4082915

The use of evoked potentials in the management of patients with severe cerebral trauma.

A W de Weerd, C Groeneveld.   

Abstract

Evoked potentials (SEP and BAEP) were measured daily in 18 patients who had suffered severe craniocerebral trauma, but could not be examined neurologically due to a barbiturate coma or neuromuscular blockade. The BAEP had only limited value as an indicator of the prognosis for these patients. The N20 component of the SEP appeared to be more valuable in this respect. Serial registration of the EPs was also of prognostic significance and proved to play an important role in the decision to stop or continue the barbiturate coma. In some patients serial measurement of the EPs also gave an indication of the presence of late posttraumatic intracranial mass lesions. EPs are useful for the monitoring of cerebral functions in patients who have suffered a contusion of the brain and can no longer be assessed clinically.

Entities:  

Mesh:

Year:  1985        PMID: 4082915     DOI: 10.1111/j.1600-0404.1985.tb00906.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

Review 1.  Are somatosensory evoked potentials the best predictor of outcome after severe brain injury? A systematic review.

Authors:  B G Carter; W Butt
Journal:  Intensive Care Med       Date:  2005-04-22       Impact factor: 17.440

2.  Brainstem auditory evoked response and vestibulo-ocular reflex in severe head injury patients. A prospective study of 60 cases.

Authors:  A K Mahapatra; P N Tandon
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

3.  Evoked potentials in post-traumatic coma.

Authors:  M Lorenz; M R Gaab
Journal:  Neurosurg Rev       Date:  1989       Impact factor: 3.042

4.  The combined monitoring of brain stem auditory evoked potentials and intracranial pressure in coma. A study of 57 patients.

Authors:  L García-Larrea; F Artru; O Bertrand; J Pernier; F Mauguière
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.